medical-imaging-ai
(4)
Cleerly
Cleerly is a Denver-based digital healthcare company using FDA-cleared artificial intelligence to analyze coronary CT scans and non-invasively measure plaque, stenosis and the likelihood of ischemia in the heart's arteries. Founded in 2017 by cardiologist James K. Min, the company builds machine-learning software that turns a routine CCTA scan into a quantitative, vessel-by-vessel picture of coronary artery disease - aiming to catch atherosclerosis earlier and help physicians prevent heart attacks rather than react to them.
DexaFit
DexaFit is a health-testing company that turns a quick, low-radiation full-body DXA scan into a broad picture of a person's health - body composition, bone density, visceral fat and metabolic markers. Its AI arm, DexaFit Dx, layers machine learning on top of those same scans to screen for major chronic diseases such as coronary artery disease and type 2 diabetes, aiming to catch them early and non-invasively. Founded in Chicago in 2011 and now operating dozens of centers, DexaFit pairs in-person testing with an app that translates results into longevity scores, disease-risk estimates and trackable goals.
Vista AI
Vista AI (formerly HeartVista) builds AI software that automates MRI exams so any technologist can capture consistent, high-quality scans without a specialist on site. Spun out of Stanford's Magnetic Resonance Systems Research Lab in 2012, its FDA-cleared cardiac MRI product turns a manual, expert-dependent procedure into a largely automated one, and the company is expanding into brain, prostate and spine imaging. Backed by Khosla Ventures and a roster of major U.S. health systems, Vista AI positions automation as a fix for the gap between soaring MRI demand and a shortage of skilled technologists.
Bunkerhill Health
Bunkerhill Health is a San Francisco AI company building the 'system of action' for hospitals. Its Carebricks platform lets health systems create, share, and deploy AI agents that turn routine data - especially CT scans already sitting in the archive - into actionable clinical findings. Born out of Stanford's Center for AI in Medicine and Imaging, the company has racked up a string of first-in-class FDA clearances for opportunistic detection of cardiovascular and bone disease, and in 2026 secured a national CMS reimbursement pathway for AI cardiovascular analysis.